Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children (Q24247433)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children (English)

0 references

0 references

1

Francine Ducharme

0 references

author name string

Franco di Salvio

series ordinal

2

0 references

publication date

26 January 2004

0 references

published in

0 references

cites work

Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of montelukast and beclomethasone on airway function and asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Worldwide clinical experience with the first marketed leukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of oral montelukast on airway function in acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Desloratadine: A new, nonsedating, oral antihistamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

The role of leukotrienes in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of montelukast and budesonide on airway responses and airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Preventive monotherapy with montelukast versus DNCG in children with mild asthma. Results of and exploratory pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Leukotrienes in the pathogenesis of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Antileukotrienes in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Clinical and symptom measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Challenge studies of a leukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Childhood asthma and allergic rhinitis: the role of leukotrienes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Scheduled follow-up after a pediatric emergency department visit for asthma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

What is new since the last (1999) Canadian Asthma Consensus Guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Models for estimating the number of unpublished studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Glucocorticoids and growth in asthmatic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Integrated plasma cortisol concentration in children with asthma receiving long‐term inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Evaluation of efficacy of traditional Chinese medicines in the treatment of childhood bronchial asthma: clinical trial, immunological tests and animal study. Taiwan Asthma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

The etiology and control of bronchial hyperresponsiveness in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Short-term growth and collagen turnover in asthmatic adolescents treated with the inhaled glucocorticoid budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

Determination of Pranlukast and its metabolites in human plasma by LC/MS/MS with PROSPEKT on-line solid-phase extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

7 January 2021

Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

7 January 2021

Glucocorticoid-induced attenuation of mucosal exudation of fibrinogen and bradykinins in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

7 January 2021

Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

7 January 2021

Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

7 January 2021

Oral vs inhaled asthma therapy. Pros, cons and combinations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

7 January 2021

Management of asthma with zafirlukast. Clinical experience and tolerability profile

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002314.PUB2

7 January 2021